Clinical trial
A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast…
NCT00102219 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00102219 |
|---|---|
| Title | A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer |
| Official title | A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Doxorubicin |
| Enrollment | 77 |
| Start date | Oct 1, 2004 |
| Completion | Oct 1, 2007 |
| First posted | Jan 26, 2005 |
| Last update posted | Nov 30, 2007 |
| Countries | Brazil, Greece, Hungary, Peru, Poland, Spain, Venezuela |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: